Physician profile
Patrick Lau
NPI 1447212212
$10,496.14
in general payments reported to CMS, 2019-2025
52 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $1,170 · 2021: $1,437 · 2022: $1,279 · 2023: $2,000 · 2024: $1,647 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,258 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,257.91 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,378.80 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,234.53 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $910.42 | 2019-2025 | |
| Lilly USA, LLC | $902.20 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $681.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $667.47 | 2019-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.46 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $454.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $413.10 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $367.02 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astellas Pharma US INC | $338.06 | 2022-2024 | Veozah |
| Allergan, INC. | $212.13 | 2019-2020 | |
| Exact Sciences Corporation | $178.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $172.95 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Currax Pharmaceuticals LLC | $145.31 | 2025 | Contrave |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.